Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies

被引：0
|
作者：
Zhitao Ying
Ting He
Xiaopei Wang
Wen Zheng
Ningjing Lin
Meifeng Tu
Yan Xie
Lingyan Ping
Chen Zhang
Weiping Liu
Lijuan Deng
Meng Wu
Feier Feng
Xin Leng
Tingting Du
Feifei Qi
Xuelian Hu
Yanping Ding
Xin-an Lu
Yuqin Song
Jun Zhu
机构：
[1] Peking University Cancer Hospital & Institute,Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing)
[2] Beijing Immunochina Pharmaceuticals Co.,undefined
[3] Ltd.,undefined
来源：
BMC Cancer | / 21卷
关键词：
CAR-T; Biodistribution; B-ALL; B-NHL; Blood;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Bispecific targeting of CD20 and CD19 increases polyfunctionality of chimeric antigen receptor T-cell products in B-cell malignancies
    Zurko, Joanna C.
    Xu, Huiqing
    Chaney, Katherine
    Schneider, Dina
    Szabo, Aniko
    Hari, Parameswaran
    Johnson, Bryon D.
    Shah, Nirav N.
    CYTOTHERAPY, 2022, 24 (08) : 767 - 773
  • [22] CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives
    Mohamad Mohty
    Jordan Gautier
    Florent Malard
    Mahmoud Aljurf
    Ali Bazarbachi
    Christian Chabannon
    Mohamed A. Kharfan-Dabaja
    Bipin N. Savani
    He Huang
    Saad Kenderian
    Arnon Nagler
    Miguel-Angel Perales
    Leukemia, 2019, 33 : 2767 - 2778
  • [23] CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives
    Mohty, Mohamad
    Gautier, Jordan
    Malard, Florent
    Aljurf, Mahmoud
    Bazarbachi, Ali
    Chabannon, Christian
    Kharfan-Dabaja, Mohamed A.
    Savani, Bipin N.
    Huang, He
    Kenderian, Saad
    Nagler, Arnon
    Perales, Miguel-Angel
    LEUKEMIA, 2019, 33 (12) : 2767 - 2778
  • [24] Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy
    Hay, Kevin A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 183 (03) : 364 - 374
  • [25] A preclinical study of allogeneic CD19 chimeric antigen receptor double-negative T cells as an off-the-shelf immunotherapy drug against B-cell malignancies
    Wang, Dan
    Wang, Liuyang
    Liu, Shuai
    Tong, Jianjun
    Zhu, Honglin
    Xu, Man
    Li, Xiancai
    Xiang, Zhiqiang
    Sun, Qinghua
    Wang, Hengcai
    Wang, Yuli
    Wang, Shuyang
    Yang, Liming
    CLINICAL & TRANSLATIONAL IMMUNOLOGY, 2024, 13 (12)
  • [26] CD19 Chimeric Antigen Receptor Therapy for Refractory Aggressive B-Cell Lymphoma
    Jacobson, Caron A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04) : 328 - +
  • [27] How to integrate CD19 specific chimeric antigen receptor T cells with other CD19 targeting agents in diffuse large B-cell lymphoma?
    de Ramon Ortiz, Carmen
    Wang, Sisi
    Stathis, Anastasios
    Bertoni, Francesco
    Zenz, Thorsten
    Novak, Urban
    Simonetta, Federico
    HEMATOLOGICAL ONCOLOGY, 2024, 42 (01)
  • [28] Chimeric Antigen Receptor-Modified T Cells in CLL
    Yeh, Chi Chun
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (20): : 1937 - 1937
  • [29] Pharmacology of Chimeric Antigen Receptor-Modified T Cells
    Song, Edward Z.
    Milone, Michael C.
    ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 61, 2021, 2021, 61 : 805 - 829
  • [30] Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy
    Hay, Kevin A.
    Hanafi, Laila-Aicha
    Li, Daniel
    Gust, Juliane
    Liles, W. Conrad
    Wurfel, Mark M.
    Lopez, Jose A.
    Chen, Junmei
    Chung, Dominic
    Harju-Baker, Susanna
    Cherian, Sindhu
    Chen, Xueyan
    Riddell, Stanley R.
    Maloney, David G.
    Turtle, Cameron J.
    BLOOD, 2017, 130 (21) : 2295 - 2306
12345